IBIO vs IR · rev $100.0K vs P/E 49, rev $3.90B
iBio, Inc. Common Stock (IBIO) versus Ingersoll Rand Inc (IR) — a side-by-side from cached financials, not a winner call.
iBio, Inc. Common Stock (IBIO) is a biotechnology company listed on US.
Ingersoll Rand Inc (IR) is a specialty industrial machinery company listed on US.
Latest reported IBIO revenue for 2026-06-30 was $100.0K. Net income was -$32.8M. Revenue was down 75.0% from 2025-06-30 to 2026-06-30. IBIO currently screens at market cap $13.4M.
Latest reported IR revenue for 2026-06-30 was $3.90B. Net income was $448.9M. IR currently screens at market cap $28.27B and trailing P/E 48.8.
IBIO currently screens at market cap $13.4M. IR currently screens at market cap $28.27B and trailing P/E 48.8.
Not investment advice. Open the IBIO and IR stock pages for the full models.
Not investment advice.